Print

International Trade Committee

The IGBA International Trade Committee aims to develop a more competitive business environment for the generic and biosimilar medicines industries around the globe. 

Its purpose is to foster the spread of generic and biosimilar medicines worldwide increasing their market penetration through the dismantling of barriers to trade, regulatory harmonization, reduction of costs linked to administrative burdens and red tape, and a fair balance between IPR protection and public health needs.  To accomplish this, the generic and biosimilar medicines industries require particular attention and a high level of collaboration and coordination among the different regional Associations and their Member companies. 

The IGBA International Trade Committee, by virtue of its global perspective, will develop coordinated strategies for the achievements of such goals.

Documents

IGBA Files Recommendations for USTR 2016 Special 301 Review – February 5, 2016

Statement by the International Generic and Biosimilar Medicines Association on the Signing of the Trans-Pacific Partnership Agreement – February 4, 2016

Report: Fostering International Trade in Generic and Biosimilar Medicines – September 2015

IGPA Recommendations for Office of the United States Trade Representative 2015 Special 301 Review

IGPA Statement on the Trans-Pacific Partnership (TPP) Negotiations

Joint EGA & GPHA response to the EU-US high level working group on jobs and growth on regulatory issues

IGPA Strategic Interest Statement for the TTIP negotiations

Contact Info

IGBA | INTERNATIONAL GENERIC AND BIOSIMILAR MEDICINES ASSOCIATION

Rue d'Arlon, 50
B-1000 Brussels, Belgium

Telephone: +32 (0)2 736 84 11
Fax: +32 (0)2 736 74 38
E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.